mip-1β

Maraviroc (Selzentry) 是一种 C-C 趋化因子受体 5 拮抗剂，具有抑制HIV 的活性。

TAK-779 (Takeda 779) 是一种非肽类CCR5和CXCR3 拮抗剂，对CCR5的Ki 值为 1.1 nM，并选择性抑制R5 HIV-1。

BX471 hydrochloride (ZK-811752 hydrochloride) is a potent, selective non-peptide CCR1 antagonist (Ki: 1 nM for human CCR1). It shows 250-fold selectivity for CCR1 over CCR2, CCR5, and CXCR4.

TAK-220 is a selective and orally bioavailable CCR5 antagonist (IC50s: 3.5 nM and 1.4 nM for inhibition on the binding of RANTES and MIP-1α to CCR5, respectively).

MIP-1072 is the prostate-specific membrane antigen inhibitor.

MIP-1095 is the prostate-specific membrane antigen inhibitor.

MIP-1095 I-131 is a small molecule PSMA inhibitor.

MIP-1095 I-123, as a radiotracer, is under investigation in clinical trial NCT00712829 (Evaluating the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents).

Met-RANTES (human) acetate 为Met-RANTES (human)的醋酸盐版本，它是CCR1和CCR5的有效拮抗剂。该化合物能够抑制人类趋化因子MIP-1α和MIP-1β，其IC50值分别为5 nM和2 nM。此外，Met-RANTES (human) acetate 也能减缓骨质破坏及缓解大鼠佐剂诱导的关节炎(AIA)的症状。

TLR4agonist-1 (TEA) (compound 17a)为Toll-like Receptor 4 (TLR4)的高效激动剂，在RAW 264.7及MM6细胞中能有效促进MIP-1β的生成。

TLR4agonist-1 (compound 17a)是一种针对Toll-like Receptor 4 (TLR4)的高效激动剂，能有效激发RAW 264.7与MM6细胞产生MIP-1β。

BC-1293作为E3连接酶亚基FBXO24的抑制剂,能够破坏FBXO24与天冬氨酰-tRNA合成酶(DARS2)之间的相互作用,并增加DARS2的表达水平.此外,BC-1293还能提升小鼠体内IL-1β、IL-9、MIP-2及TNFα的水平,显示出免疫刺激的活性.